While modern medicine increasingly uses automated machines and devices to treat a wide variety of illnesses, the equipment itself can sometimes be linked to dangerous or even fatal issues. The public relies on federal regulators to adequately monitor these types of issues and ultimately ensure patient safety, but when that oversight fails, the consequences can be deadly.
PBC is pleased to announce that its own Chris Coffin has been appointed to the Plaintiffs' Steering Committee that will take the lead on all federal Taxotere litigation for plaintiffs throughout the U.S.
Taxotere, a chemotherapy drug manufactured by Sanofi-Aventis and primarily used to treat breast cancer, is linked to permanent hair loss or "alopecia" in women who were undergoing treatment for breast cancer.
We have handled claims on behalf of individuals exposed to the commercial herbicide and weed killer, Roundup, on their farm, home or on the job and who were diagnosed with certain cancers. Roundup, or glyphosate, has been recently scientifically linked to Non-Hodgkin's Lymphoma and other cancers.
Class members who submitted timely and valid claims for the pediatric Celexa, Lexapro settlement began receiving checks on June 27, 2016. The class action accused Celexa and Lexapro manufacturer, Forest Laboratories, of improperly marketing the medications to minors under the age of 18. The plaintiffs are represented by Baum, Hedlund, Aristei & Goldman, PC and Pendley, Baudin & Coffin, L.L.P. Click here to read more.
Patrick Pendley of Pendley, Baudin & Coffin, L.L.P. presented a $290,000 check to ARC-Iberville after winning a class action settlement filed against British Petroleum after the spill in the Gulf of Mexico.
Law360, New York (May 9, 2016, 4:05 PM ET) -- Health care fund providers seeking to recover money lost because of Forest Laboratories' allegedly fraudulent promotion of its drugs in treating pediatric depression pressed a Massachusetts federal judge to certify their portion of the multidistrict litigation as a class, saying previous court rulings and
The lawyers at Pendley, Baudin and Coffin LLP are representing women across the country who have suffered severe permanent hair loss (alopecia) as a result of taking Taxotere, a chemotherapy drug used to treat multiple forms of cancer. Each Taxotere hair loss case will be given the individual care and attention that it deserves and will not be pursued as part of a class action lawsuit.
PBC's Chris Coffin is part of a panel of attorneys that will present on the current state of Taxotere litigation at the 2016 Mass Torts Made Perfect conference.
PBC recently filed one of the first Taxotere lawsuits in the nation, alleging it causes permanent hair loss in some women who were treated with the drug while undergoing chemotherapy.
The lawsuit contends that the manufacturer of Taxotere, Sanofi-Aventis, did not warn patients and physicians properly of the risks associated with taking the drug and permanent alopecia.
Chris Coffin of Pendley, Baudin & Coffin was a speaker at a Taxotere Hair Loss Litigation Webinar held Thursday, March 10, 2016. Lawyers litigating Taxotere cases presented a range of topics. Included were overview of the case, intake, Taxotere toxicity and causation, state of the litigation, all about Sanofi Aventis, generic vs. brand name, etc.
Patrick W. Pendley participated in the American Bar Association seminar on March 10, 2016 in New Orleans, entitled "Class Action Litigation in America-A National Symposium". Pendley appeared on a panel with The Honorable Eldon E.